GlassScriptPhysician profile
Michael T Sinopoli
NPI 1245268085
$4,775.07
in general payments reported to CMS, 2019-2025
34 companies · $1,091 in 2025
The $1,091 reported for 2025 was more than what 84% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,995 · 2020: $211 · 2021: $44.88 · 2022: $142 · 2023: $604 · 2024: $687 · 2025: $1,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,382.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,382.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $1,899.98 | 2019-2024 | Optune |
| Regeneron Healthcare Solutions, INC. | $424.68 | 2023-2025 | Libtayo |
| Novartis Pharmaceuticals Corporation | $320.68 | 2023-2025 | |
| Gilead Sciences, INC. | $225.46 | 2024-2025 | Trodelvy |
| Hologic INC | $211.43 | 2020 | |
| Visionrt, INC. | $199.25 | 2019 | |
| Genentech USA, INC. | $153.36 | 2023-2025 | Venclexta, Tecentriq, Phesgo |
| Regeneron Pharmaceuticals, INC. | $148.95 | 2025 | Libtayo |
| Exelixis INC. | $148.22 | 2021-2025 | Cabometyx |
| Astrazeneca Pharmaceuticals LP | $120.23 | 2023-2025 | Imfinzi, Calquence, Tagrisso |
| Daiichi Sankyo INC. | $91.93 | 2023-2024 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $79.46 | 2025 | Talvey, Darzalex, Rybrevant |
| Sobi, INC | $69.44 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $67.32 | 2024 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $59.28 | 2024 | Fruzaqla |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $58.70 | 2024-2025 | |
| Emd Serono, INC. | $54.70 | 2023-2024 | Bavencio |
| Incyte Corporation | $50.09 | 2023-2025 | Jakafi, Monjuvi |
| Amgen INC. | $49.12 | 2022-2023 | Vectibix, Xgeva, Nplate |
| Advanced Accelerator Applications | $39.69 | 2019 | |
| Astellas Pharma US INC | $32.58 | 2023 | Xtandi, Padcev |
| Adaptive Biotechnologies Corporation | $32.47 | 2025 | Clonoseq |
| Tactile Systems Technology INC | $24.44 | 2024 | Flexitouch Plus, Entre Plus |
| Agios Pharmaceuticals, INC. | $24.35 | 2024 | Pyrukynd |
| Lilly USA, LLC | $24.21 | 2025 | |
| Sun Pharmaceutical Industries INC. | $24.20 | 2023 | Odomzo, Yonsa |
| E.R. Squibb & Sons, L.L.C. | $24.04 | 2024 | Opdualag |
| Celgene Corporation | $23.88 | 2022 | |
| Glaxosmithkline, LLC. | $17.43 | 2024 | Ojjaara |
| Blueprint Medicines Corporation | $16.60 | 2023 | Ayvakit |
| Stemline Therapeutics INC. | $16.26 | 2025 | Orserdu |
| Galvanize Therapeutics, INC | $14.66 | 2024 | Aliya System |
| Alexion Pharmaceuticals, INC. | $14.29 | 2024 | Ultomiris |
| Abbvie INC. | $13.69 | 2023 | Lupron Depot |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sinopoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.